Table 2.
Mean concentrations of biomarkers at baseline determined in both groups of the study population
| Biomarkers | Microalbuminuria (n = 172) | Controls (n = 188) | P | Bonferroni-Holm correction |
|---|---|---|---|---|
| S100A8/MRP8, ng/ml | 94.77 ± 60.89 | 93.40 ± 65.79 | 0.650 | >0.999 |
| Endostatin, ng/ml | 121.2 ± 38.99 | 108.9 ± 31.91 | 0.005 | 0.075 |
| VAP-1, ng/ml | 624.6 ± 170.0 | 653.6 ± 169.6 | 0.090 | >0.999 |
| CXCL-16, ng/ml | 2.67 ± 0.61 | 2.16 ± 0.72 | <0.001 | <0.001 |
| sTNF-RI, ng/ml | 1.43 ± 0.46 | 1.39 ± 0.59 | 0.018 | 0.270 |
| sTNF-RII, ng/ml | 3.12 ± 1.02 | 2.97 ± 0.85 | 0.138 | >0.999 |
| sST2, ng/ml | 15.87 ± 8.24 | 13.74 ± 4.90 | 0.048 | 0.720 |
| sThrombomodulin, ng/ml | 4.59 ± 1.22 | 4.39 ± 0.92 | 0.257 | >0.999 |
| VEGF, pg/ml | 298.3 ± 170.6 | 276.9 ± 171.95 | 0.186 | >0.999 |
| RAGE, ng/ml | 1.10 ± 0.41 | 1.06 ± 0.47 | 0.272 | >0.999 |
| VEGF-R1, pg/ml | 90.72 ± 26.09 | 86.02 ± 38.87 | 0.059 | 0.885 |
| TGF-β1, ng/ml | 33.21 ± 13.14 | 23.57 ± 18.99 | <0.001 | <0.001 |
| Angiopoietin-2, ng/ml | 2.30 ± 1.30 | 1.85 ± 0.91 | <0.001 | <0.001 |
| Angiopoietin-1, ng/ml | 39.47 ± 12.84 | 39.94 ± 13.92 | 0.623 | >0.999 |
| MCP-1, pg/ml | 407.9 ± 120.3 | 378.3 ± 132.9 | 0.004 | 0.060 |
CXCL-16, C-X-C motif chemokine ligand 16; MCP-1, monocyte chemotactic protein 1; RAGE, receptor for advanced glycation endproducts; S100A8/MRP8, S100 calcium binding protein A8/myeloid related protein 8; sTNF-RI, soluble tumor necrosis factor receptor I; sTNF-RII, soluble tumor necrosis factor receptor II; sST2, soluble ST2; TGF-β1, transforming growth factor beta 1; VAP-1, vascular adhesion protein 1; VEGF-A, vascular endothelial growth factor-A; VEGF-R1, vascular endothelial growth factor-A receptor 1.
Data are presented as mean (SD) for normally distributed values or and n (%) for categoric values. Statistically significant differences are in bold.